甲状腺乳头状癌患者外周血2型固有淋巴样细胞含量分析
Analysis of Type 2 Innate Lymphoid Cells in Peripheral Blood of Patients with Papillary Thyroid Carcinoma
DOI: 10.12677/acm.2025.15123663, PDF,   
作者: 李 艳：青岛大学基础医学院免疫学系，山东 青岛；临沂市妇幼保健院检验科，山东 临沂；陈小燕, 杨贵艳：临沂市妇幼保健院检验科，山东 临沂；彭宝相*：临沂市肿瘤医院检验科，山东 临沂
关键词: 甲状腺乳头状癌；2型固有淋巴样细胞；流式细胞术；GATA3；肿瘤免疫；Papillary Thyroid Carcinoma； Type 2 Innate Lymphoid Cells； Flow Cytometry； GATA3； Tumor Immunity
摘要: 目的：探讨甲状腺乳头状癌(PTC)患者外周血中2型固有淋巴样细胞(ILC2)的表达水平及其临床意义。方法：收集30例PTC患者和20例健康对照者的外周血标本，采用流式细胞术和实时荧光定量PCR (qPCR)检测ILC2的比例及其关键转录因子GATA3的mRNA表达水平。结果：PTC患者外周血中ILC2比例及GATA3 mRNA表达均显著低于健康对照组(P < 0.05)。结论：ILC2在PTC患者外周血中表达减低，可能参与疾病的发生发展过程，或具有作为潜在生物标志物的价值。
Abstract: Objective: To investigate the expression of type 2 innate lymphoid cells (ILC2s) in the peripheral blood of patients with papillary thyroid carcinoma (PTC) and its clinical relevance. Methods: Peripheral blood samples were collected from 30 PTC patients and 20 healthy controls. The frequency of ILC2s and the mRNA expression of GATA3 were detected by flow cytometry and quantitative real-time PCR (qPCR), respectively. Results: The proportion of ILC2s and the expression level of GATA3 mRNA in the PTC group were significantly lower than those in the control group (P < 0.05). Conclusion: The decreased expression of ILC2s in peripheral blood may be associated with the pathogenesis of PTC and could serve as a potential biomarker for the disease.
文章引用：李艳, 陈小燕, 杨贵艳, 彭宝相. 甲状腺乳头状癌患者外周血2型固有淋巴样细胞含量分析[J]. 临床医学进展, 2025, 15(12): 2355-2360. https://doi.org/10.12677/acm.2025.15123663

参考文献

[1] Boucai, L., Zafereo, M. and Cabanillas, M.E. (2024) Thyroid Cancer: A Review. Journal of the American Medical Association, 331, 425-435. [Google Scholar] [CrossRef] [PubMed]
[2] Jacquelot, N., Seillet, C., Vivier, E. and Belz, G.T. (2022) Innate Lymphoid Cells and Cancer. Nature Immunology, 23, 371-379. [Google Scholar] [CrossRef] [PubMed]
[3] 王妍雯, 强思远, 付阳荷, 等. 固有淋巴样细胞抗肿瘤免疫新进展[J]. 肝脏, 2022, 27(12): 1252-1257.
[4] Calvi, M., Di Vito, C., Frigo, A., Trabanelli, S., Jandus, C. and Mavilio, D. (2022) Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer. Frontiers in Immunology, 13, Article 914266. [Google Scholar] [CrossRef] [PubMed]
[5] 郭会, 臧利超, 杨歆煜, 等. 外周血固有淋巴样细胞(ILC)平衡失调维持免疫抑制状态促进肺腺癌发展[J]. 细胞与分子免疫学杂志, 2023, 39(8): 729-736.
[6] Chevalier, M.F., Trabanelli, S., Racle, J., Salomé, B., Cesson, V., Gharbi, D., et al. (2017) ILC2-Modulated T Cell-to-MDSC Balance Is Associated with Bladder Cancer Recurrence. Journal of Clinical Investigation, 127, 2916-2929. [Google Scholar] [CrossRef] [PubMed]
[7] Amisaki, M., Zebboudj, A., Yano, H., Zhang, S.L., Payne, G., Chandra, A.K., et al. (2025) IL-33-Activated ILC2s Induce Tertiary Lymphoid Structures in Pancreatic Cancer. Nature, 638, 1076-1084. [Google Scholar] [CrossRef] [PubMed]
[8] Jou, E., Rodriguez-Rodriguez, N., Ferreira, A.F., Jolin, H.E., Clark, P.A., Sawmynaden, K., et al. (2022) An Innate IL-25-ILC2-MDSC Axis Creates a Cancer-Permissive Microenvironment for Apc Mutation-Driven Intestinal Tumorigenesis. Science Immunology, 7, eabn0175. [Google Scholar] [CrossRef] [PubMed]
[9] Trabanelli, S., Chevalier, M.F., Derré, L. and Jandus, C. (2019) The Pro-and Anti-Tumor Role of ILC2s. Seminars in Immunology, 41, Article 101276. [Google Scholar] [CrossRef] [PubMed]
[10] Fiordi, B., Salvestrini, V., Gugliotta, G., Castagnetti, F., Curti, A., Speiser, D.E., et al. (2023) IL-18 and VEGF-A Trigger Type 2 Innate Lymphoid Cell Accumulation and Pro-Tumoral Function in Chronic Myeloid Leukemia. Haematologica, 108, 2396-2409. [Google Scholar] [CrossRef] [PubMed]
[11] Roy, R., Das, T. and Biswas, N. (2024) Orchestration of Immune Response by Innate Lymphoid Cell Subtype 2 at Various Tumor Microenvironment, a Suitable Target for Cancer Immunotherapy. International Reviews of Immunology, 43, 74-82. [Google Scholar] [CrossRef] [PubMed]
[12] Korchagina, A.A., Shein, S.A., Koroleva, E. and Tumanov, A.V. (2023) Transcriptional Control of ILC Identity. Frontiers in Immunology, 14, Article 1146077. [Google Scholar] [CrossRef] [PubMed]
[13] Moral, J.A., Leung, J., Rojas, L.A., Ruan, J., Zhao, J., Sethna, Z., et al. (2020) ILC2s Amplify PD-1 Blockade by Activating Tissue-Specific Cancer Immunity. Nature, 579, 130-135. [Google Scholar] [CrossRef] [PubMed]
[14] Salimi, M., Wang, R., Yao, X., Li, X., Wang, X., Hu, Y., et al. (2018) Activated Innate Lymphoid Cell Populations Accumulate in Human Tumour Tissues. BMC Cancer, 18, Article No. 341. [Google Scholar] [CrossRef] [PubMed]
[15] Arlauckas, S.P., Garris, C.S., Kohler, R.H., Kitaoka, M., Cuccarese, M.F., Yang, K.S., et al. (2017) In Vivo Imaging Reveals a Tumor-Associated Macrophage-Mediated Resistance Pathway in Anti-Pd-1 Therapy. Science Translational Medicine, 9, eaal3604. [Google Scholar] [CrossRef] [PubMed]

为你推荐